Prognostic Nomogram of Extranodal NK/T-cell Lymphoma
NCT04554511 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2023-06-18
Summary
This study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL patients.
Conditions
- Extranodal NK/T-cell Lymphoma
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Principal Investigators
-
Hua Wang · Sun Yat-sen University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-08-28
- Primary Completion
- 2024-01-01
- Completion
- 2024-01-01
Countries
- China
Study Locations
More Related Trials
-
Risk Stratification of Nodal PTCL
NCT03040206 ·Status: COMPLETED
-
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
NCT02085655 ·Status: UNKNOWN ·Phase: PHASE3
-
Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma
NCT04484506 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
NCT04414969 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
NCT05149170 ·Status: UNKNOWN ·Phase: PHASE2
-
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
NCT05254899 ·Status: UNKNOWN ·Phase: PHASE2
-
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
NCT02560441 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma
NCT04511351 ·Status: UNKNOWN ·Phase: NA
-
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
NCT04365036 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Nasopharyngeal Carcinoma From Guangdong
NCT03003182 ·Status: UNKNOWN
-
Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy
NCT02229682 ·Status: UNKNOWN ·Phase: PHASE2
-
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
NCT02631239 ·Status: UNKNOWN ·Phase: PHASE3
-
Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma
NCT03936452 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
NCT06197776 ·Status: RECRUITING
-
Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study
NCT05417139 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
NCT02845856 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma
NCT02705508 ·Status: UNKNOWN ·Phase: PHASE2
-
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer
NCT03007836 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II Study of Nasal NK/T-cell Lymphoma
NCT00292695 ·Status: COMPLETED ·Phase: PHASE2
-
Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
NCT04127227 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC
NCT04833257 ·Status: COMPLETED ·Phase: PHASE2
-
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
NCT06069830 ·Status: RECRUITING ·Phase: NA
-
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
NCT05211232 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients
NCT03925896 ·Status: UNKNOWN ·Phase: PHASE1
-
Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma
NCT04554524 ·Status: UNKNOWN ·Phase: PHASE4